NDA 009402 · Ph Health
Delestrogen
Estradiol Valerate · Injection
Last checked: Nov 19, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1954
Jul 15, 1954
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,683
345 Phase 3, 172 recruiting
FAERS reports
778
525 serious, 19 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses [see WARNINGS , Malignant neoplasms , Endometrial cancer ]. CARDIOVASCULAR AND OTHER RISKS Estrogens and progestins should not be used for the prevention of cardiovascular disease [see WARNINGS , Cardiovascular disorders ]. The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women...
What it is approved for
From the label in effect May 13, 2026.
INDICATIONS AND USAGE DELESTROGEN (estradiol valerate injection, USP) is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 15, 1954 Original approval
3 products under this application
- DELESTROGEN · ESTRADIOL VALERATE 40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued · TE AO
- DELESTROGEN · ESTRADIOL VALERATE 20MG/ML · INJECTABLE, INJECTION · Prescription · TE AO
- DELESTROGEN · ESTRADIOL VALERATE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AO
Clinical trials
Interventional ClinicalTrials.gov studies with "Estradiol Valerate" as an intervention, any sponsor and status, largest first.
- Short-term Effects of Transdermal Estradiol on Female COVID-19 PatientsPivotal-lookingCompleted
Istanbul University - CerrahpasaAcademic, hospital or other
NCT05774405 · 9,169 participants · Start Jul 1, 2020 · Primary completion Jul 31, 2021
Drug: Climara 0.1Mg/24Hr Transdermal System · For: COVID-19; Hormone Replacement Therapy
Sites: Istanbul, Turkey (Türkiye)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptivePivotal-lookingTerminated
Organon and CoIndustry
NCT05264506 · 3,055 participants · Start Feb 17, 2022 · Primary completion Jan 12, 2024
Drug: NOMAC-E2 COC · For: Contraception
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 103 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
- Heart and Estrogen-Progestin Replacement Study (HERS)Pivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00319566 · 2,430 participants · Start Jul 1992
Drug: Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily · For: Coronary Heart Disease
Sites: San Francisco, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use96
- headache72
- drug ineffective71
- fatigue65
- nausea59
- pain53
- migraine45
- dyspnoea42
- weight increased39
- diarrhoea36
- abdominal pain30
- anxiety30
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 10 |
| 2006 | 10 |
| 2007 | 21 |
| 2008 | 17 |
| 2009 | 13 |
| 2010 | 22 |
| 2011 | 18 |
| 2012 | 39 |
| 2013 | 11 |
| 2014 | 27 |
| 2015 | 20 |
| 2016 | 28 |
| 2017 | 28 |
| 2018 | 62 |
| 2019 | 28 |
| 2020 | 47 |
| 2021 | 55 |
| 2022 | 52 |
| 2023 | 58 |
| 2024 | 65 |
| 2025 | 77 |
| 2026 | 56 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Delestrogen (Estradiol Valerate)
2024 spending
$77K
Beneficiaries
209
475 claims
Per beneficiary
$370
$30.53 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $271,566 |
| 2021 | $255,299 |
| 2022 | $170,993 |
| 2023 | $132,341 |
| 2024 | $77,376 |
Part B: Delestrogen* (Estradiol Valerate*) · HCPCS J1380
2024 spending
$36K
Beneficiaries
524
3,086 claims
Per beneficiary
$69
2024 ASP limit $8.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $54,454 |
| 2021 | $61,587 |
| 2022 | $49,945 |
| 2023 | $50,117 |
| 2024 | $36,341 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combined oral contraceptives: update recommendations of the Latin American contraceptive association.
Palacios S, Ayala G, González G, et al. · Gynecol Endocrinol 2023 · Systematic Review
- Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women.
Gao L, Zheng T, Xue W, et al. · Climacteric 2018 · Randomized Controlled Trial
- Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.
Cohen MA, Edelman A, Paynter R, et al. · Cochrane Database Syst Rev 2023 · Systematic Review
- Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.
Ramanadhan S, Hansen K, Henderson JT, et al. · Cochrane Database Syst Rev 2023 · Systematic Review
- Estrogens and men with schizophrenia: is there a case for adjunctive therapy?
Kulkarni J, de Castella A, Headey B, et al. · Schizophr Res 2011 · Comparative Study, Randomized Controlled Trial
- Effects of testosterone treatment on endometrial proliferation in postmenopausal women.
Zang H, Sahlin L, Masironi B, et al. · J Clin Endocrinol Metab 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Ph Health
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.